Journal article
Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients
Journal of cachexia, sarcopenia and muscle, Vol.9(2), pp.358-368
04/2018
DOI: 10.1002/jcsm.12251
PMCID: PMC5879958
PMID: 29316343
Abstract
Cancer-associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulating levels of a number of inflammatory cytokines have been associated with cancer cachexia, these associations were generally made in patients with advanced disease and thus may be associated with disease progression rather than directly with the cachexia syndrome. Thus, we sought to assess potential biomarkers of cancer-induced cachexia in patients with earlier stages of disease.
A custom multiplex array was used to measure circulating levels of 25 soluble factors from 70 pancreatic cancer patients undergoing attempted tumour resections. A high-sensitivity multiplex was used for increased sensitivity for nine cytokines.
Resectable pancreatic cancer patients with cachexia had low levels of canonical pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1β (IL-1β), interferon-γ (IFN-γ), and tumour necrosis factor (TNF). Even in our more sensitive analysis, these cytokines were not associated with cancer cachexia. Of the 25 circulating factors tested, only monocyte chemoattractant protein-1 (MCP-1) was increased in treatment-naïve cachectic patients compared with weight stable patients and identified as a potential biomarker for cancer cachexia. Although circulating levels of leptin and granulocyte-macrophage colony-stimulating factor (GM-CSF) were found to be decreased in the same cohort of treatment-naïve cachectic patients, these factors were closely associated with body mass index, limiting their utility as cancer cachexia biomarkers.
Unlike in advanced disease, it is possible that cachexia in patients with resectable pancreatic cancer is not associated with high levels of classical markers of systemic inflammation. However, cachectic, treatment-naïve patients have higher levels of MCP-1, suggesting that MCP-1 may be useful as a biomarker of cancer cachexia.
Details
- Title: Subtitle
- Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients
- Creators
- Erin E Talbert - The Ohio State UniversityHeather L Lewis - The Ohio State UniversityMatthew R Farren - Emory UniversityMitchell L Ramsey - The Ohio State UniversityJeffery M Chakedis - The Ohio State UniversityPriyani Rajasekera - The Ohio State UniversityEricka Haverick - The Ohio State UniversityAngela Sarna - The Ohio State UniversityMark Bloomston - 21st Century Oncology (United States)Timothy M Pawlik - The Ohio State UniversityTeresa A Zimmers - Indiana UniversityGregory B Lesinski - Emory UniversityPhil A Hart - The Ohio State UniversityMary E Dillhoff - The Ohio State UniversityCarl R Schmidt - The Ohio State UniversityDenis C Guttridge - The Ohio State University
- Resource Type
- Journal article
- Publication Details
- Journal of cachexia, sarcopenia and muscle, Vol.9(2), pp.358-368
- DOI
- 10.1002/jcsm.12251
- PMID
- 29316343
- PMCID
- PMC5879958
- NLM abbreviation
- J Cachexia Sarcopenia Muscle
- ISSN
- 2190-5991
- eISSN
- 2190-6009
- Grant note
- P30 CA016058 / NCI NIH HHS R01 CA194593 / NCI NIH HHS T32 CA106196 / NCI NIH HHS T32 CA090223 / NCI NIH HHS R01 CA180057 / NCI NIH HHS R01 CA122596 / NCI NIH HHS
- Language
- English
- Date published
- 04/2018
- Academic Unit
- Fraternal Order of Eagles Diabetes Research Center; Health, Sport, and Human Physiology ; Internal Medicine
- Record Identifier
- 9984259396302771
Metrics
15 Record Views